Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of CYP2C19 polymorphism on escitalopram pharmacokinetics and pharmacodynamics
2006-001976-19Phase 4Completed
- Sponsor
- Clinical Pharmacology, University of Southern Denmark
- Start
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of escitalopram in major depressive disorder (MDD), sponsored by Clinical Pharmacology, University of Southern Denmark. Primary endpoints: Effect of CYP2C19 phenotypes on escitalopram pharmacokinetics and Effect of CYP2C19 phenotypes on escitalopram pharmacodynamics. Started May 2006; status: completed.
02
Drugs
escitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2006-001976-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001976-19.